Novel, Self-Assembling Dimeric Inhibitors of Human β Tryptase

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Pharmacology

Background:

• Beta-tryptase is a homotetrameric serine protease with four active sites.
• Its structure is amenable to designing bivalent inhibitors that target adjacent sites.

Purpose of the Study:

• To design and synthesize novel heterodimeric inhibitors for beta-tryptase.
• To evaluate the potency, selectivity, and mechanism of these bivalent inhibitors.

Main Methods:

• Utilized diol, hydroxymethyl phenols, benzoyl methyl hydroxamates, and boronic acid chemistries.
• Employed target-driven combinatorial chemistry to screen numerous ligand combinations.
• Validated inhibition mechanism using X-ray crystallography.
• Assessed compound efficacy in HMC1 xenograft models.

Main Results:

• Successfully produced self-assembling heterodimeric beta-tryptase inhibitors.
• Achieved superior activity and >100-fold potency improvement compared to monomeric inhibitors.
• Demonstrated high selectivity against related proteases and good target engagement.
• Identified combinations yielding nanomolar inhibition.

Conclusions:

• Heterodimeric inhibitors represent a potent strategy for beta-tryptase targeting.
• Combinatorial chemistry is effective for developing bivalent small-molecule drugs.
• These inhibitors show therapeutic potential for tryptase-related conditions.